
Sign up to save your podcasts
Or


Despite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidelines are constantly scrutinized and reassessed. The most current U.S. Preventative Services Task Force (USPSTF) guidelines recommend screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk HPV testing, or every 5 years with high-risk HPV testing with cytology.
To get the full picture on how gynecologists and oncologists today are navigating screening guidelines and new treatment options with their patients, Oncology Times interviewed Deana Gerber, MD, an obstetrics and gynecology specialist at NYU Langone Health’s Perlmutter Cancer Center. Gerber treats women who have cancer of the reproductive tract and who have been diagnosed with a genetic mutation that increases their risk of gynecologic cancer. She offers preventive treatments and risk-reducing surgery as a routine part of her care approach. She discussed how oncologists can approach conversations around screening and address the issue of screening overuse and underuse.
This episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Annual Meeting highlights. First Up, results from the ECOG-ACRIN E1910 Randomized Phase III clinical trial showed that blinatumomab improved overall survival in newly diagnosed adult patients with b-lineage acute lymphoblastic leukemia.
First author of this new research, Mark Litzow, MD, from the Mayo Clinic in Rochester, MN, talked with journalist Peter Goodwin at the ASH Annual Meeting. They discussed the use of blinatumomab in patients whose initial therapy for acute lymphoblastic leukemia had achieved minimum residual disease—MRD (Abstract LBA-1).
Next, researchers explored the potential of using genomic DNA and RNA profiles in a machine-learning algorithm to predict which patients with acute myeloid leukemia or advanced myelodysplastic syndrome will respond to venetoclax-based therapy (Abstract 2789). Maher Albitar, MD, discussed the findings.
Moving on, the downside of curative therapy for Hodgkin's lymphoma was under discussion at ASH. The conference heard about “epigenetic age” and neurocognitive function in young adults previously treated for Hodgkin's disease. OncTimes Talk correspondent Peter Goodwin asked first author of a report on this, Annalynn M. Williams, PhD, from the University of Rochester, in New York, about the impact of standard treatments on the subsequent lives of children (Abstract 902).
Finally, we interviewed James McCloskey, MD, from the John Theurer Cancer Center at Hackensack University Medical Center, about the results of the V-Mast study showing the value of combining CPX-351 with midostaurin for high-risk acute myeloid leukemia. In this Phase III study in older adults with newly diagnosed, high-risk/secondary AML, CPX-351 significantly improved overall survival and remission rates versus conventional 7+3 chemotherapy, with a comparable safety profile (Abstract 1436).
A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new study, David Sallman, MD, from the Moffitt Cancer Center in Tampa, Florida, had reported the new findings at the 2022 Annual Meeting of the American Society of Hematology, OncTimes Talk correspondent Peter Goodwin interviewed him about the study and about the overall prospects of using CAR-T cells to treat AML.
PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (CAR)-T simultaneously expressing a CAR specifically targeting CD33; membrane bound IL-15 (mbIL15) for enhanced in vivo expansion and persistence; and a kill switch to conditionally eliminate CAR-T cells for an improved safety profile. CD33 is over-expressed on AML blasts with lesser expression on normal hematopoietic
Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening, the colonoscopy, reduces cancer deaths by 67 percent, according to a 2018 study from Kaiser Permanente. So, we know screening is effective. However, obstacles remain. Colonoscopies are invasive and costs can be prohibitive. An alarming trend has also emerged, with incidence of early-onset colorectal cancer increasing over the last few decades.
Today on OncTimes Talk, we interview Anil K. Rustgi, MD, on the current state of colorectal cancer screening, advancements in non-invasive testing, and the mechanisms behind early-onset colorectal cancer.
In addition to being a world-renowned leader in the field of gastrointestinal oncology, Rustgi is the Director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center. His research focuses on tumor initiation, the tumor microenvironment, and tumor metastasis in gastrointestinal cancers.
BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational drug ipatasertib—in a Phase I study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarter of the patients treated with the AKT blocker had their tumors shrink. These included patients with breast, endometrial, and salivary gland cancers. Tumors remained stable in just over half of the remaining patients. The presenting author at the Barcelona symposium, Carolyn McCourt, MD, Associate Professor of Obstetrics and Gynecology at Washington University in St. Louis, talked with OncTimes Talk reporter Peter Goodwin.
BARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for hematologic malignancies and solid tumors, according to findings from a study of circulating tumor DNA reported at the European Organization for Research and Treatment of Cancer—National Cancer Institute—American Association for Cancer Research (EORTC-NCI-AACR) 2022 Symposium on Molecular Targets and Cancer Therapeutics. Marco Tagliamento, MD, medical oncologist and research fellow at the Gustave Roussy Institute, France, told the symposium about study findings from the large Gustave Roussy Molecular Tumor Board dataset able to identify genetic mutations involved in clonal hematopoiesis.
Tagliamento told the conference 113 patients—8 percent of their total—were found to have had at least one clonal hematopoiesis mutation that could be considered to place them at higher risk of developing hematologic malignancies. “Out of these patients, 45 were referred to our hematology unit by their oncologist and five were subsequently diagnosed with blood cancer: one with myelomonocytic leukemia, two with myelodysplastic syndrome and two with essential thrombocythemia,” Tagliamento told the symposium. Journalist Peter Goodwin briefly interviewed Tagliamento on his findings at EORTC-NCI-AACR.
In oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Although breast cancer mortality rates decreased by 43 percent from 1989 to 2020, Black women remain more likely to die from breast cancer compared with White women, according to the 2022 American Cancer Society’s update on breast cancer statistics in the United States.
What is the underlying cause of disparities in breast cancer? It comes down to a variety of factors, from screening disparities and clinical trial participation to differences in genetics and biology. Today on OncTimes Talk, we sit down with Lisa A. Newman, MD, MPH, FACS, FASCO, to discuss each of these categories and explore how oncologists and the medical community at large can finally close the gap.
Newman is a world-renowned surgical oncologist and was appointed Chief of the Section of Breast Surgery at NewYork-Presbyterian/Weill Cornell Medical Center
We talk to Naveen Pemmaraju, MD, about the results of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp in adults with treatment-naive and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BBPDCN is a rare and aggressive myeloid malignancy of the dendritic cell lineage which can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. The disease carries a poor prognosis, and although it has been treated with combination leukemia or lymphoma chemotherapy regimens, these often result in nondurable responses with high rates of relapse.
Oncology Times journalist Catlin Nalley sat down with Pemmaraju to discuss his most recent study titled “Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm,” recently published in the Journal of Clinical Oncology (2022; doi: 10.1200/JCO.22.00034). Pemmaraju is Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center and has dedicated his career to the study of rare and ultra-rare cancers.
Today on OncTimes Talk, we are getting to know a clinical researcher in 5 questions. We sat down with Sandeep Mittan, PhD, FAHA, who is a Clinical Scientist in the Division of Women’s Health and Medical Oncology at the Montefiore Medical Center and The University Hospital for Albert Einstein College of Medicine in New York. His work investigates mechanisms responsible for aging and cardiovascular pathologies. We discuss the unique characteristics of his patient population, new cardio-oncology devices and treatment options, and the ongoing obstacle of medical skepticism.
From the publisher's feed